Free Trial

ACADIA Pharmaceuticals Inc. $ACAD Shares Sold by Pictet Asset Management Holding SA

ACADIA Pharmaceuticals logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Pictet Asset Management cut its ACADIA Pharmaceuticals stake by 82.7% in the third quarter, selling 1.64 million shares and retaining 343,086 shares worth about $6.9 million.
  • Despite Pictet’s sale, institutional investors and hedge funds own 96.71% of the company’s stock; several firms, including BlackRock, established new positions.
  • ACADIA reported quarterly EPS of $0.31 and revenue of $342.3 million, beating analyst estimates, with revenue up 22.8% year over year. Analysts’ consensus rating was “Moderate Buy,” with an average price target of $31.34.
  • MarketBeat previews the top five stocks to own by December 1st.

Pictet Asset Management Holding SA reduced its position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 82.7% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 343,086 shares of the biopharmaceutical company's stock after selling 1,640,112 shares during the quarter. Pictet Asset Management Holding SA owned about 0.20% of ACADIA Pharmaceuticals worth $6,936,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the company. BlackRock Inc. acquired a new stake in ACADIA Pharmaceuticals in the second quarter valued at approximately $569,634,000. Palo Alto Investors LP bought a new stake in shares of ACADIA Pharmaceuticals during the second quarter valued at approximately $72,461,629. Bank of America Corp DE bought a new stake in shares of ACADIA Pharmaceuticals during the second quarter valued at approximately $32,900,000. First Trust Advisors LP increased its holdings in shares of ACADIA Pharmaceuticals by 47.3% during the first quarter. First Trust Advisors LP now owns 3,343,868 shares of the biopharmaceutical company's stock valued at $74,435,000 after acquiring an additional 1,073,834 shares in the last quarter. Finally, Bank of New York Mellon Corp acquired a new position in shares of ACADIA Pharmaceuticals during the second quarter worth approximately $19,244,000. 96.71% of the stock is owned by institutional investors and hedge funds.

ACADIA Pharmaceuticals Stock Performance

Shares of NASDAQ ACAD opened at $18.75 on Monday. The stock has a market cap of $3.24 billion, a price-to-earnings ratio of 8.89 and a beta of 0.87. ACADIA Pharmaceuticals Inc. has a fifty-two week low of $15.85 and a fifty-two week high of $30.96. The firm's 50-day simple moving average is $21.79 and its 200 day simple moving average is $23.37.

ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last issued its quarterly earnings data on Wednesday, November 4th. The biopharmaceutical company reported $0.31 EPS for the quarter, topping analysts' consensus estimates of $0.20 by $0.11. The firm had revenue of $342.30 million during the quarter, compared to analyst estimates of $332.58 million. ACADIA Pharmaceuticals had a return on equity of 8.90% and a net margin of 30.13%. The company's revenue for the quarter was up 22.8% on a year-over-year basis. During the same period in the previous year, the company posted $0.42 EPS. On average, sell-side analysts predict that ACADIA Pharmaceuticals Inc. will post 0.76 EPS for the current year.

Analyst Upgrades and Downgrades

ACAD has been the topic of a number of research reports. Deutsche Bank lowered their target price on ACADIA Pharmaceuticals from $38.00 to $31.00 and set a "buy" rating on the stock in a research report on Friday, September 25th. Needham & Company LLC reissued a "buy" rating and issued a $35.00 price target on shares of ACADIA Pharmaceuticals in a research report on Monday, October 19th. UBS Group downgraded shares of ACADIA Pharmaceuticals from a "buy" rating to a "neutral" rating and reduced their price target for the company from $49.00 to $23.00 in a research report on Tuesday, October 13th. Weiss Ratings restated a "hold (c+)" rating on shares of ACADIA Pharmaceuticals in a research note on Tuesday, November 10th. Finally, William Blair set a $33.00 price target on shares of ACADIA Pharmaceuticals in a research note on Monday, September 28th. Thirteen equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company's stock. According to data from MarketBeat, ACADIA Pharmaceuticals currently has an average rating of "Moderate Buy" and an average price target of $31.34.

Check Out Our Latest Analysis on ACADIA Pharmaceuticals

Insider Transactions at ACADIA Pharmaceuticals

In related news, EVP Mark Schneyer sold 3,321 shares of the company's stock in a transaction on Friday, October 30th. The stock was sold at an average price of $20.88, for a total transaction of $69,342.48. Following the completion of the sale, the executive vice president owned 71,322 shares in the company, valued at approximately $1,489,203.36. This represents a 4.45% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 26.20% of the company's stock.

ACADIA Pharmaceuticals Profile

(Free Report)

ACADIA Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing medicines for neurological and rare diseases. Founded in 1993 and headquartered in San Diego, California, the company conducts research and development alongside its commercial operations. Its marketed products include NUPLAZID (pimavanserin), approved in the United States to treat hallucinations and delusions associated with Parkinson's disease psychosis, and DAYBUE (trofinetide), a treatment for Rett syndrome.

Featured Stories

Institutional Ownership by Quarter for ACADIA Pharmaceuticals (NASDAQ:ACAD)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in ACADIA Pharmaceuticals Right Now?

Before you consider ACADIA Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ACADIA Pharmaceuticals wasn't on the list.

While ACADIA Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines